The objective of this project is to determine whether the integration of quantitative characteristics derived rom neuroimaging parameters (magnetic resonance spectroscopic indices, cerebral blood volume and apparent diffusion coefficient), with tissue biomarkers and are predictive of the biologic behavior for patients with glioblastoma multiforme (GBM) post therapy. Standard magnetic resonance imaging (MRI) is limited in assessing the biological behavior of increased enhancement which universally occurs post therapy. Although in the majority of cases this is secondary to tumor progression, following focal therapies such as convection enhanced delivery(CED) of agents, increased enhancement could be secondary to treatment effects. Pathologic specimens obtained post therapy in areas of new enhancement often consist of both 'tumor"""""""" and """""""" treatment effect"""""""". There are currently no well-established biomarkers that distinguish between tumor or treatment effect or are predictive of the behavior of the radiographic changes post therapy. In this project the objectives will be accomplished by the evaluation of metabolic and physiologic imaging parameters to differentiate between treatment related changes and recurrent tumor. If physiologic imaging can be correlated with tumor biology or clinical outcome, this will allow for the repeated use of a safe, non- invasive, easily acquired biomarker. This will have significant implications to the care of patients and the design, conduct and interpretation of clinical trials in Neuro-Oncology. Patients with radiographically defined progression"""""""" will be studied prior to treatment for recurrence and followed for clinical outcome to determine if specific parameters are predictive of biological behavior. This information will give insight into the imaging methods required for evaluation of the effects of CED of a novel compound and prospective physiologic imaging is planned before and after treatment in a clinical trial of CED. These studies will require the support of the Clinical Services Core and the Imaging and Tissue Correlate Core

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA118816-02
Application #
7666967
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2008-07-01
Budget End
2009-06-30
Support Year
2
Fiscal Year
2008
Total Cost
$212,875
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Park, Ilwoo; Larson, Peder E Z; Gordon, Jeremy W et al. (2018) Development of methods and feasibility of using hyperpolarized carbon-13 imaging data for evaluating brain metabolism in patient studies. Magn Reson Med 80:864-873
Hayes, Josie; Yu, Yao; Jalbert, Llewellyn E et al. (2018) Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. Neuro Oncol 20:632-641
Mancini, Andrew; Xavier-Magalhães, Ana; Woods, Wendy S et al. (2018) Disruption of the ?1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner. Cancer Cell 34:513-528.e8
Vareth, Maryam; Lupo, Janine; Larson, Peder et al. (2018) A comparison of coil combination strategies in 3D multi-channel MRSI reconstruction for patients with brain tumors. NMR Biomed 31:e3929
Li, Yan; Lafontaine, Marisa; Chang, Susan et al. (2018) Comparison between Short and Long Echo Time Magnetic Resonance Spectroscopic Imaging at 3T and 7T for Evaluating Brain Metabolites in Patients with Glioma. ACS Chem Neurosci 9:130-137
Gordon, Jeremy W; Chen, Hsin-Yu; Autry, Adam et al. (2018) Translation of Carbon-13 EPI for hyperpolarized MR molecular imaging of prostate and brain cancer patients. Magn Reson Med :
Choi, Serah; Yu, Yao; Grimmer, Matthew R et al. (2018) Temozolomide-associated hypermutation in gliomas. Neuro Oncol 20:1300-1309
Zhang, Chenan; de Smith, Adam J; Smirnov, Ivan V et al. (2017) Non-additive and epistatic effects of HLA polymorphisms contributing to risk of adult glioma. J Neurooncol 135:237-244
Autry, Adam; Phillips, Joanna J; Maleschlijski, Stojan et al. (2017) Characterization of Metabolic, Diffusion, and Perfusion Properties in GBM: Contrast-Enhancing versus Non-Enhancing Tumor. Transl Oncol 10:895-903
Anwar, Mekhail; Molinaro, Annette M; Morin, Olivier et al. (2017) Identifying Voxels at Risk for Progression in Glioblastoma Based on Dosimetry, Physiologic and Metabolic MRI. Radiat Res 188:303-313

Showing the most recent 10 out of 75 publications